Dengvaxia

Dengvaxia is a vaccine designed to prevent dengue fever, a mosquito-borne viral infection. This live, attenuated vaccine is administered subcutaneously and is suitable for individuals at risk of dengue exposure.

Dengvaxia is primarily used for the prevention of dengue fever, a viral infection transmitted by mosquitoes. It is intended for individuals who are at risk of exposure to the dengue virus, particularly in regions where the disease is endemic. The vaccine works by stimulating the immune system to produce a protective response against the dengue virus.

Common effects of Dengvaxia may include mild to moderate injection site reactions such as pain, redness, or swelling. Some individuals may also experience general symptoms like headache, fatigue, or muscle pain following vaccination. These effects are typically temporary and resolve on their own.

Dengvaxia should be administered by healthcare professionals trained in vaccination procedures. It is important to inform your healthcare provider about any allergies or medical conditions before receiving the vaccine. Individuals with weakened immune systems or those who have had severe allergic reactions to previous vaccines should consult their healthcare provider before receiving Dengvaxia.

Dengvaxia may interact with other medications or vaccines. It is advisable to discuss all current medications, including over-the-counter drugs and supplements, with a healthcare provider before receiving the vaccine. Additionally, individuals should avoid taking immune-suppressing medications around the time of vaccination, as this could affect the vaccine's effectiveness.